Cara Therapeutics Announces Presentation at American Society of Nephrology Kidney Week 2020
October 21, 2020 16:01 ET
|
Cara Therapeutics, Inc.
- Results from global KALM-2 pivotal Phase 3 trial of KORSUVA™ Injection in hemodialysis patients with pruritus to be presented – - NDA submission for KORSUVA Injection on track for fourth quarter...
Vifor Pharma and Cara Therapeutics sign US license agreement for IV Korsuva™* to treat dialysis patients with pruritus
October 20, 2020 01:00 ET
|
Cara Therapeutics, Inc.
Vifor Pharma secures commercial rights for IV Korsuva in non-Fresenius Medical Care dialysis clinics representing approx. 66% of the market, under a profit-sharing arrangement with CaraCara will...
Cara Therapeutics Appoints Thomas Reilly as Chief Financial Officer
October 01, 2020 07:00 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
Cara Therapeutics Reports Second Quarter 2020 Financial Results
August 10, 2020 16:01 ET
|
Cara Therapeutics, Inc.
– Conference call today at 4:30 p.m. ET – STAMFORD, Conn., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and...
Cara Therapeutics to Present at the Canaccord Genuity 40th Annual Growth Conference
August 06, 2020 16:01 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
Cara Therapeutics to Announce Second Quarter 2020 Financial Results on August 10, 2020
August 03, 2020 16:01 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
Cara Therapeutics Expands Board of Directors with Appointment of Susan Shiff, Ph.D., M.B.A.
June 30, 2020 07:00 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., June 30, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
Cara Therapeutics Announces Completion of Interim Statistical Assessment for KARE Phase 2 Trial of Oral KORSUVA™ in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus
June 17, 2020 07:00 ET
|
Cara Therapeutics, Inc.
- Patient enrollment increased approximately 28% to maintain >80% statistical power for primary endpoint and key registration endpoint of >4-point improvement responder analysis - - Full...
Cara Therapeutics to Present at the Jefferies Virtual Healthcare Conference
May 27, 2020 16:01 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., May 27, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
Cara Therapeutics Reports First Quarter 2020 Financial Results
May 11, 2020 16:01 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., May 11, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...